Search

Your search keyword '"Castañeda, S."' showing total 51 results

Search Constraints

Start Over You searched for: Author "Castañeda, S." Remove constraint Author: "Castañeda, S." Publisher bmj publishing group ltd and european league against rheumatism Remove constraint Publisher: bmj publishing group ltd and european league against rheumatism
51 results on '"Castañeda, S."'

Search Results

1. OP0014 TRANSCRIPTS EXPRESSED IN TEMPORAL ARTERY BIOPSIES ASSOCIATED WITH RESPONSE TO THERAPY IN PATIENTS WITH GIANT CELL ARTERITIS

2. POS1007 THE INVOLVEMENT OF THE C5 AND C5AR1 GENES IN THE PATHOGENESIS OF IgAV

3. AB1240 NLRP3 AND CASP1 GENES AS DISCRIMINATORY MARKERS BETWEEN IGA VASCULITIS AND IGA NEPHROPATHY?

4. AB0694 BARICITINIB IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 60 PATIENTS

5. POS0111 BENEFICIAL EFFECT OF TEMPORARY METHOTREXATE WITHDRAWAL ON B AND T CELL RESPONSES UPON SARS-CoV-2 VACCINATION IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIATIC ARTHRITIS

6. AB1318 EFFECTIVENESS OF TOCILIZUMAB IN AORTITIS AND ANEURYSMS ASSOCIATED WITH GIANT CELL ARTERITIS. MULTICENTER OPEN-LABEL STUDY

7. POS0077 EFFECTIVENESS OF JANUS KINASE INHIBITORS IN RELAPSING GIANT CELL ARTERITIS IN REAL-WORLD CLINICAL PRACTICE AND REVIEW OF THE LITERATURE

8. POS0256 THE FIRST METHYLOME PROFILING STUDY OF B-CELLS IN IGA VASCULITIS REVEALED POTENTIAL BIOMARKERS OF DISEASE SUSCEPTIBILITY

9. AB1000 ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS. SPANISH NATIONAL REGISTRY IN A REAL-WORLD SETTING

10. POS1375 THE WINDOW OF OPPORTUNITY: A CONCEPT ALSO APPLICABLE TO UNDIFFERENTIATED ARTHRITIS

11. AB1278 THE ROLE OF NLRP1 POLYMORPHISMS IN THE PATHOGENESIS OF GIANT CELL ARTERITIS

12. POS0689 WINDOW OF OPPORTUNITY IN THE TREATMENT OF RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE WITH ABATACEPT. NATIONAL MULTICENTER STUDY OF 526 PATIENTS

13. OP0025 GENOME-WIDE DNA METHYLATION STUDY REVEALS SPECIFIC SIGNATURES IN THE AFFECTED ARTERIAL TISSUE OF GIANT CELL ARTERITIS PATIENTS

14. POS1424 TOCILIZUMAB IN EXTRACRANIAL LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: COMPARATIVE MULTICENTER STUDY

15. POS0925 VISUAL MANIFESTATIONS IN GIANT CELL ARTERITIS: IDENTIFICATION OF RISK FACTORS FROM THE ARTESER REGISTRY

18. POS0035 INFLUENCE OF INTERSTITIAL LUNG DISEASE DURATION ON THE TREATMENT OF RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 392 PATIENTS WITH ABATACEPT

19. POS0835 EFFECTIVENESS AND SAFETY OF JAK INHIBITORS IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 57 PATIENTS

20. OP0102 IDENTIFICATION OF NEW RISK LOCI AND PATHWAYS INVOLVED IN GCA PATHOGENESIS BY A GENOME-WIDE STUDY

21. AB0709 EFFECTIVENESS OF JANUS KINASE INHIBITORS IN GIANT CELL ARTERITIS IN CLINICAL PRACTICE. REAL-WORLD CLINICAL PRACTICE STUDY AND LITERATURE REVIEW

22. OP0126 LONG-TERM FOLLOW UP OF ABATACEPT IN USUAL INTERSTITIAL PNEUMONIA ASSOCIATED TO RHEUMATOID ARTHRITIS. NATIONAL MULTICENTER STUDY OF 172 PATIENTS

23. POS0363 SEX DIFFERENCES IN CARDIOVASCULAR AND DISEASE-RELATED FEATURES IN AXIAL SPONDYLOARTHRITIS. A MULTICENTERSTUDYOF 912 PATIENTS

24. POS0808 MICA/B-DEPENDENT ACTIVATION OF CYTOTOXIC NATURAL KILLER CELLS BY INFLAMMATORY CDC2 CONTRIBUTE TO PRIMARY SJÖGREN´S SYNDROME PATHOLOGY

25. POS1112 COMBINED BIOLOGICAL OR TARGETED THERAPY IN SPONDYLOARTHRITIS: EXPERIENCE FROM A MULTICENTER CASE SERIES IN SPAIN

26. POS1030 DNA-METHYLATION PROFILING IN THE BLOOD OF PATIENTS WITH RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE

27. POS0864 EFFECTIVENESS OF ANTIFIBROTICS IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 50 PATIENTS IN CLINICAL PRACTICE

28. AB0166 IGAV AND IGAN: A SINGLE ENTITY REGARDING CD40, BLK AND BANK1 POLYMORPHISMS

32. AB1148 Biological treatment of non ischaemic optic neuritisassociated to immune-mediated inflammatory diseases. multicenter study

34. OP0051 Evolution of the vascular involvement objectified by pet/tac in patients with giant cell arteritis treated with tocilizumab

36. THU0282 The impact of comorbidities on physical function in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PSA) attending rheumatology clinics

37. THU0439 Tocilizumab in giant cell arteritis. national multicenter study of 134 patients of clinical practice

38. FRI0500 Extracranial vascular affection in giant cell arteritis

39. THU0186 Rheumatoid arthritis and interstitial lung disease. multicentric retrospective study of 118 patients treated with biological no anti tnf

41. AB0108 Decreased expression of PTPN22 gene in patients with rheumatoid arthritis carrying the risk allele of PTPN22 RS2488457 polymorphism

42. SAT0458 Identification of genetic variation specifically associated with psoriatic arthritis using genome-wide association studies

43. SAT0316 Angii involvement in lung endothelial dysfunction and pah development in psgl-1 deficient female mice

45. AB0723 Technical aids agreed among specialists for the management of comorbidity in patients with axial spondyloarthritis: the gecoax project

46. SAT0387 “do not do” recommendations in the management of comorbidity in patients with axial spondyloarthritis. gecoax project

47. OP0209-HPR Incidence of first cardiovascular event in spanish patients with chronic inflammatory rheumatic diseases: prospective data from the carma project

48. FRI0336 Efficacy of tocilizumab in 31 patients with giant cell arteritis

50. SAT0191 Patterns of interstitial lung disease in rheumatoid arthritis and abatacept. multicenter study of 63 patients

Catalog

Books, media, physical & digital resources